# Senseonics Holdings, Inc. Schedules First Quarter 2026 Earnings Release and Conference Call for May 7, 2026 at 4:30 P.M. Eastern Time
Canonical URL: https://biopharmsignal.com/news/SENS/senseonics-holdings-inc-schedules-first-quarter-2026-earnings-release-and-confer-40b588f2
Ticker: SENS
Company: Senseonics
Source: Senseonics
Published: 2026-05-01 13:10 EST
## Summary

Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on the development,...

## Article Body
Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its first quarter 2026 financial results after market close on Thursday, May 7, 2026.

Management will hold a conference call to review the Company’s first quarter 2026 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on Senseonics Holdings, Inc. website at www.senseonics.com by navigating to “Investor Relations,” and then “Events & Publications,” and will be archived there for future reference. To listen to the conference call, please dial 1-800-225-9448 (US/Canada) or 1-203-518-9708 (International), passcode SENSQ1, approximately ten to five minutes prior to start time.

About Senseonics Senseonics Holdings, Inc. ("Senseonics") is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics' CGM systems Eversense ® 365 and Eversense ® E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.

Senseonics Investor Contact

Jeremy Feffer LifeSci Advisors investors@senseonics.com
## Recent Company News
- 2026-06-10 12:00 EST — [Senseonics and Welldoc Partner to Develop Next-Generation App for Eversense® 365](https://biopharmsignal.com/news/SENS/senseonics-and-welldoc-partner-to-develop-next-generation-app-for-eversense-365-6acf0328) — Source: Senseonics
- 2026-06-06 21:00 EST — [Real-World Evidence of Eversense 365 Presented at ADA Demonstrating Strong Performance and Patient Impact in Both Open and Closed Loop Systems](https://biopharmsignal.com/news/SENS/real-world-evidence-of-eversense-365-presented-at-ada-demonstrating-strong-perfo-37d528e7) — Source: Senseonics
- 2026-06-01 12:00 EST — [Senseonics Highlights Analyst Event and Oral Presentation of Eversense 365 Real-World Evidence at ADA 2026](https://biopharmsignal.com/news/SENS/senseonics-highlights-analyst-event-and-oral-presentation-of-eversense-365-real--5826a5ba) — Source: Senseonics
- 2026-05-07 20:01 EST — [Senseonics Holdings, Inc. Reports First Quarter 2026 Financial Results](https://biopharmsignal.com/news/SENS/senseonics-holdings-inc-reports-first-quarter-2026-financial-results-a7b4bee3) — Source: Senseonics
- 2026-05-04 20:01 EST — [Senseonics Announces Closing of $92 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares](https://biopharmsignal.com/news/SENS/senseonics-announces-closing-of-92-million-public-offering-and-full-exercise-of--0e1d5fdd) — Source: Senseonics
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)